Onward Medical Publishes ARCIM data on blood pressure regulation in Nature Medicine

Onward announced two publications of detailed results from the clinical feasibility studies of ARC-IM therapy in blood pressure regulation in Nature and Nature Medicine. The publications build on the previously reported interim results, and continue to highlight the benefit of the ARC-IM system for SCI patients that have blood pressure instability. Note that ARC-IM for blood pressure instability is the next in line indication for Onward, where a pivotal (Empower BP) study is due to start by YE25, with an interim analysis planned for 2H26, and could lead to an accelerated path to market. We reiterate our €10.4 TP and BUY rating.